Chemotherapy Resistance in Osteogenic Sarcoma and Other Solid Tumors
Sponsor: Columbia University
Listed as NCT00580385, this observational or N/A phase trial focuses on Osteosarcoma and remains ongoing. Sponsored by Columbia University, it has been updated 15 times since 1997, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Study Description(click to expand)When tumor tissue known or presumed to be a primary or secondary bone cancer or solid tumor with known elevated intra-tumoral pressure such as retinoblastoma is being removed or has been removed for diagnostic or therapeutic reasons a small sample of it will be obtained for this study. The tumor samples will be used to study in vitro, determinants of chemotherapy resistance and oncogenesis. These determinants will be correlated with histologic response to preoperative chemotherapy and clinical outcome (event free survival). In addition, blood samples (20ml) may be obtained before or after the procedure.
When tumor tissue known or presumed to be a primary or secondary bone cancer or solid tumor with known elevated intra-tumoral pressure such as retinoblastoma is being removed or has been removed for diagnostic or therapeutic reasons a small sample of it will be obtained for this study. The tumor samples will be used to study in vitro, determinants of chemotherapy resistance and oncogenesis. These determinants will be correlated with histologic response to preoperative chemotherapy and clinical outcome (event free survival). In addition, blood samples (20ml) may be obtained before or after the procedure.
Status Flow
Change History
15 versions recorded-
May 4, 2026 — Present [daily]
Active Not Recruiting
Phase: NA → None
-
Oct 2025 — May 2026 [monthly]
Active Not Recruiting NA
-
Oct 2024 — Oct 2025 [monthly]
Active Not Recruiting NA
-
Sep 2024 — Oct 2024 [monthly]
Active Not Recruiting NA
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting NA
▶ Show 10 earlier versions
-
Oct 2023 — Jul 2024 [monthly]
Active Not Recruiting NA
-
Sep 2022 — Oct 2023 [monthly]
Active Not Recruiting NA
-
Oct 2021 — Sep 2022 [monthly]
Active Not Recruiting NA
-
Jan 2021 — Oct 2021 [monthly]
Active Not Recruiting NA
-
Oct 2020 — Jan 2021 [monthly]
Active Not Recruiting NA
-
Oct 2019 — Oct 2020 [monthly]
Active Not Recruiting NA
-
Nov 2018 — Oct 2019 [monthly]
Active Not Recruiting NA
Status: Recruiting → Active Not Recruiting
-
Oct 2018 — Nov 2018 [monthly]
Recruiting NA
-
Jun 2018 — Oct 2018 [monthly]
Recruiting NA
-
Jan 2017 — Jun 2018 [monthly]
Recruiting NA
First recorded
Aug 1997
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
The purpose of this study is to investigate tumors in the laboratory to determine how and why they respond, or fail to respond to different drug therapies. This study will also investigate why high pressure develops within tumors and how this affects how well drugs work. We will also take blood samples before and/or after your procedure to measure biochemical factors that may help us predict the behavior of osteogenic sarcoma and other solid tumors.
Contact Information
- Columbia University
- Hospital for Special Surgery, New York
- Memorial Sloan Kettering Cancer Center
- Rockefeller University
- Weill Medical College of Cornell University
For direct contact, visit the study record on ClinicalTrials.gov .